Clinical trial
Feasibility Study on the Use of Redormin® 500 (Ze 91019) on Day-time Cognition and Quality of Life in People With Occasional Sleep Problems
NCT05684523 is registered in ClinicalTrials.gov with Max Zeller Soehne AG as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility Study on the Use of Redormin® 500 (Ze 91019) on Day-time Cognition and Quality of Life in People With Occasional Sleep Problems
- Lead sponsor
- Max Zeller Soehne AG
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 1, 2023
- Completion date
- December 20, 2023
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.